CA1323300C - Thrombolytically active combination of pro-uk and uk - Google Patents
Thrombolytically active combination of pro-uk and ukInfo
- Publication number
- CA1323300C CA1323300C CA000548421A CA548421A CA1323300C CA 1323300 C CA1323300 C CA 1323300C CA 000548421 A CA000548421 A CA 000548421A CA 548421 A CA548421 A CA 548421A CA 1323300 C CA1323300 C CA 1323300C
- Authority
- CA
- Canada
- Prior art keywords
- pro
- unit dosage
- injection
- urokinase
- infusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 148
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 148
- 229960005356 urokinase Drugs 0.000 claims abstract description 148
- 239000007924 injection Substances 0.000 claims abstract description 34
- 238000002347 injection Methods 0.000 claims abstract description 34
- 238000001802 infusion Methods 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 108010073863 saruplase Proteins 0.000 claims abstract description 9
- 102000009123 Fibrin Human genes 0.000 claims description 10
- 108010073385 Fibrin Proteins 0.000 claims description 10
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 10
- 230000009089 cytolysis Effects 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 229950003499 fibrin Drugs 0.000 claims description 10
- 229960002897 heparin Drugs 0.000 claims description 10
- 229920000669 heparin Polymers 0.000 claims description 10
- 230000002195 synergetic effect Effects 0.000 claims description 8
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 abstract description 2
- 238000011260 co-administration Methods 0.000 abstract 1
- 150000002894 organic compounds Chemical class 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 238000002586 coronary angiography Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000002934 lysing effect Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003711 glyceryl trinitrate Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003462 zymogenic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868623823A GB8623823D0 (en) | 1986-10-03 | 1986-10-03 | Therapeutic lysis of fibrin blood clots |
| GB8623823 | 1986-10-03 | ||
| GB868628741A GB8628741D0 (en) | 1986-12-02 | 1986-12-02 | Therapeutic lysis of fibrin blood clots |
| GB8628741 | 1986-12-02 | ||
| GB878707551A GB8707551D0 (en) | 1987-03-30 | 1987-03-30 | Therapeutic lysis of fibrin blood clots |
| GB8707551 | 1987-03-30 | ||
| GB8715678 | 1987-07-03 | ||
| GB878715678A GB8715678D0 (en) | 1987-07-03 | 1987-07-03 | Therapeutic lysis of fibrin blood clots |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1323300C true CA1323300C (en) | 1993-10-19 |
Family
ID=27449820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000548421A Expired - Fee Related CA1323300C (en) | 1986-10-03 | 1987-10-01 | Thrombolytically active combination of pro-uk and uk |
Country Status (19)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8503097A (nl) * | 1985-11-11 | 1987-06-01 | Leuven Res & Dev Vzw | Geneesmiddel met thrombolytische werking. |
-
1987
- 1987-09-18 NL NL8702234A patent/NL8702234A/nl not_active Application Discontinuation
- 1987-09-18 HU HU874172A patent/HUT47032A/hu unknown
- 1987-09-22 DE DE19873731776 patent/DE3731776A1/de not_active Ceased
- 1987-09-28 FR FR8713486A patent/FR2605225B1/fr not_active Expired - Fee Related
- 1987-09-28 BE BE8701102A patent/BE1002058A4/fr active
- 1987-09-28 CH CH3749/87A patent/CH678599A5/de not_active IP Right Cessation
- 1987-10-01 LU LU87007A patent/LU87007A1/fr unknown
- 1987-10-01 PT PT85848A patent/PT85848B/pt unknown
- 1987-10-01 GR GR871528A patent/GR871528B/el unknown
- 1987-10-01 CA CA000548421A patent/CA1323300C/en not_active Expired - Fee Related
- 1987-10-01 IL IL84061A patent/IL84061A0/xx unknown
- 1987-10-01 SE SE8703788A patent/SE466531B/sv not_active IP Right Cessation
- 1987-10-01 FI FI874320A patent/FI874320A7/fi not_active IP Right Cessation
- 1987-10-01 NO NO874143A patent/NO874143L/no unknown
- 1987-10-02 KR KR1019870011020A patent/KR960002738B1/ko not_active Expired - Fee Related
- 1987-10-02 DK DK519287A patent/DK519287A/da not_active Application Discontinuation
- 1987-10-02 IT IT8748444A patent/IT1230114B/it active
- 1987-10-02 AU AU79325/87A patent/AU7932587A/en not_active Abandoned
- 1987-10-08 MY MYPI87002871A patent/MY101943A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE8703788L (sv) | 1988-04-04 |
| FI874320L (fi) | 1988-04-04 |
| FR2605225A1 (fr) | 1988-04-22 |
| PT85848B (en) | 1990-01-12 |
| IT1230114B (it) | 1991-10-07 |
| NL8702234A (nl) | 1988-05-02 |
| DK519287A (da) | 1988-04-04 |
| SE8703788D0 (sv) | 1987-10-01 |
| KR880004821A (ko) | 1988-06-27 |
| GR871528B (en) | 1988-02-23 |
| SE466531B (sv) | 1992-03-02 |
| FI874320A7 (fi) | 1988-04-04 |
| FR2605225B1 (fr) | 1994-02-04 |
| KR960002738B1 (ko) | 1996-02-26 |
| FI874320A0 (fi) | 1987-10-01 |
| NO874143D0 (no) | 1987-10-01 |
| IT8748444A0 (it) | 1987-10-02 |
| HUT47032A (en) | 1989-01-30 |
| IL84061A0 (en) | 1988-03-31 |
| DK519287D0 (da) | 1987-10-02 |
| DE3731776A1 (de) | 1988-05-05 |
| NO874143L (no) | 1988-04-05 |
| BE1002058A4 (fr) | 1990-06-12 |
| CH678599A5 (enrdf_load_stackoverflow) | 1991-10-15 |
| LU87007A1 (fr) | 1988-05-03 |
| AU7932587A (en) | 1988-04-14 |
| MY101943A (en) | 1992-02-15 |
| PT85848A (en) | 1987-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI120182B (fi) | Trombolyyttisesti aktiivisten proteiinien ja antikoagulanttien yhdistelmiä ja niiden käyttöjä | |
| RU96119944A (ru) | Комбинация тромболитически активных белков и антикоагулянтов и их применение | |
| US5055295A (en) | Lysis of fibrin blood clots with urokinase and pro-urokinase | |
| CA1337046C (en) | Thrombolytic agent | |
| Dupe et al. | The evaluation of plasmin and streptokinase activator complexes in a new rabbit model of venous thrombosis | |
| CA1323300C (en) | Thrombolytically active combination of pro-uk and uk | |
| GB2197195A (en) | Urokinase compositions for treating thrombosis | |
| US6372213B2 (en) | Method of treating sickle cell disease or thalassemia | |
| US20050143283A1 (en) | Activated protein c formulations | |
| JP2958650B2 (ja) | 新規な血栓溶解組成物 | |
| CA1303987C (en) | Pharmaceutical composition having thrombolytic activity | |
| JP2783367B2 (ja) | ヘパリン含有製剤 | |
| Mola et al. | A pilot study of pro-urokinase in the treatment of deep vein thrombosis | |
| EP1137432B1 (en) | Use of protein c for the treatment of thrombocytopenic purpura and hemolytic uremic syndrome | |
| EP0352897B1 (en) | Tpa-containing medicaments | |
| US5174994A (en) | Pharmaceutical composition having thrombolytic activity | |
| Sasahara | Fundamentals of fibrinolytic therapy | |
| JPH08268910A (ja) | プロテインｃの皮下投与のための薬剤 | |
| JPH0769921A (ja) | 網膜血管閉塞症予防治療剤 | |
| JPH049334A (ja) | 線溶活性増強剤 | |
| JPS63208534A (ja) | 線維素溶解剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |